Estradiol
ESTRACE
Pronunciation: es-tra-DYE-oel
“Es-trojan horse”
What it isER-alpha, ER-beta, and GPER agonist; menopausal vasomotor and genitourinary symptoms.
Why this oneTransdermal estradiol avoids hepatic first-pass effects, while vaginal forms directly treat genitourinary symptoms.
What limits itSystemic use raises thrombotic and stroke risk; add a progestogen when the uterus is present to protect the endometrium.
FDA-approved for
- menopausal symptoms (~1975)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Moderate-severe vasomotor symptoms / vulvovaginal atrophy of menopause | Adults | 1-2 mg QD, cyclic (3 wk on, 1 wk off) | Lowest effective dose | Titrated to symptoms |
| Female hypoestrogenism (hypogonadism, castration, primary ovarian failure) | Adults | 1-2 mg QD | Lowest effective maintenance dose | Titrated to symptoms |
| Breast cancer palliation (selected metastatic disease) | Adults | 10 mg TID x >=3 months | 10 mg TID | 10 mg TID |
| Advanced androgen-dependent prostate carcinoma (palliation) | Adults | 1-2 mg TID | 1-2 mg TID | 1-2 mg TID |
| Prevention of postmenopausal osteoporosis | Adults | Lowest effective dose (not determined) | Lowest effective dose | Lowest effective dose |
Renal Undefined
Hepatic Contraindicated in hepatic impairment or disease
Instructions
- Use lowest effective dose for shortest duration consistent with treatment goals
- Add a progestin in women with an intact uterus to reduce endometrial cancer risk
- Reevaluate periodically (e.g., every 3-6 months)
Available strengths
- tab 0.5, 1, 2 mg
Contraindications
- Undiagnosed abnormal genital bleeding
- Known, suspected, or history of breast cancer (except selected metastatic disease)
- Known or suspected estrogen-dependent neoplasia
- Active or history of DVT/pulmonary embolism
- Active or recent (within past year) arterial thromboembolic disease (e.g., stroke, MI)
- Liver dysfunction or disease
- Known or suspected pregnancy
Cautions
- Cardiovascular and thromboembolic events (stroke, MI, DVT/PE)
- Malignancies (endometrial, breast, ovarian)
- Gallbladder disease and pancreatitis
- Hypertriglyceridemia
- Elevated blood pressure
- Retinal vascular thrombosis / visual abnormalities
- Probable dementia (age >=65)
- Hypocalcemia; aggravation of porphyria, asthma, epilepsy
Adverse reactions
- Abnormal vaginal bleeding/spotting
- Breast tenderness/enlargement
- Nausea, abdominal cramps/bloating
- Headache/migraine
- Mood disturbances
- Thromboembolic events
- Weight change
Pregnancy Contraindicated; should not be used during pregnancy
Lactation Undefined
Cost
| Strength | #/mo | generic $/mo | CostPlus | |
|---|---|---|---|---|
| 0.5 mg | tab | 30 qd | $1.85 | offered |
| 1 mg | tab | 30 qd | $1.90 | offered |
| 2 mg | tab | 30 qd | $2.39 | offered |
Other forms: Estradiol transdermal (VIVELLE-DOT) · Estradiol vaginal (ESTRACE CREAM)
Available combined with: Norelgestromin (in XULANE patch) · drospirenone / ethinyl / estradiol · ethinyl / estradiol / etonogestrel · ethinyl / estradiol / levonorgestrel · ethinyl / estradiol / norethindrone · ethinyl / estradiol / norgestimate
Generic entryPre-1982
⚠ BOXED WARNINGS
- Endometrial cancer
- Cardiovascular disorders
- Breast cancer
- Probable dementia
Classes and tags
Clinical profile
Legacy pregnancy categoryX
Defining liabilityVenous thromboembolism and hormone-related adverse effects; estrogen also lowers lamotrigine exposure.
Open Estradiol in the interactive console ↗
